-
US policy changes put elimination of viral hepatitis at high risk Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-02-17
No Abstract
-
Letter to the editor: Alcohol a confounding factor in assessment of resmetirom therapy Hepatology (IF 12.9) Pub Date : 2025-02-17 Aleksander Krag, Nikolaj Torp, Mads Israelsen
-
Letter to the Editor: Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD practice guidance Hepatology (IF 12.9) Pub Date : 2025-02-17 Jay H. Hoofnagleand, Averell H. Sherker
-
More than a lark? LRRK2 inhibitors to treat alpha-1 antitrypsin deficiency Hepatology (IF 12.9) Pub Date : 2025-02-17 George Marek
-
Erratum: Refitting the model for end‐stage liver disease for the eurotransplant region Hepatology (IF 12.9) Pub Date : 2025-02-17 Ben F. J. Goudsmit, Hein Putter, Maarten E. Tushuizen, Serge Vogelaar, Jacques Pirenne, Alwayn Ian P. J., Bart van Hoek, Andries E. Braat
-
Revealing new biomarker to predict MASLD progression Hepatology (IF 12.9) Pub Date : 2025-02-17 Gowthami Kanagalingam, Juan Pablo Arab
-
Deep learning: Cracking the metabolic code Hepatology (IF 12.9) Pub Date : 2025-02-17 Mian B. Khalid
-
Trapped in fibrosis: How neutrophil extracellular traps drive HSC activation Hepatology (IF 12.9) Pub Date : 2025-02-17 Sofia Jerez
-
-
Liver transplantation for cholestatic liver diseases: Timing & disease recurrence Hepatology (IF 12.9) Pub Date : 2025-02-17 Guilherme Grossi Lopes Cançado, Maya Deeb, Aliya Fatemah Gulamhusein
Though rare, primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) account for 8-14% of liver transplants (LT) in North America and Europe and the journey of these patients across the peri-transplant period is unique. Equitable access to LT is an important challenge, as the MELD score and its derivatives inadequately reflect the morbidity and mortality related to these diseases
-
Erratum: CCL15 recruits suppressive monocytes to facilitate immune escape and disease progression in hepatocellular carcinoma Hepatology (IF 12.9) Pub Date : 2025-02-17 Long-Zi Liu, Zhao Zhang, Bo-Hao Zheng, Yang Shi, Men Duan, Li-Jie Ma, Zhi-Chao Wang, Liang-Qing Dong, Ping-Ping Dong, Jie-Yi Shi, Shu Zhang, Zhen-Bin Ding, Ai-Wu Ke, Ya Cao, Xiao-Ming Zhang, Ruibin Xi, Jian Zhou, Jia Fan, Xiao-Ying Wang, Qiang Gao
-
Management of alcohol use disorder: a gastroenterology and hepatology-focused perspective Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-02-13 Luis Antonio Díaz, Daniel König, Sabine Weber, Gustavo Ayares, José Miguel Fuentealba, Valeria Vázquez, Ramon Bataller, Patrick S Kamath, Gerald Scott Winder, Lorenzo Leggio, Juan Pablo Arab
Alcohol use disorder is a prevalent and major but preventable cause of morbidity and mortality worldwide, causing several important health consequences, including chronic liver disease. Despite its substantial effects, most clinicians do not adequately assess alcohol intake in clinical practice, and there are several barriers to providing integrated management to patients with alcohol use disorder
-
-
EASL Congress 2025: prepare and submit your late-breaker! J. Hepatol. (IF 26.8) Pub Date : 2025-02-14
No Abstract
-
The EASL Guidelines app is your indispensable mobile companion for accessing comprehensive and up-to-date clinical practice guidelines in hepatology. Download it now! J. Hepatol. (IF 26.8) Pub Date : 2025-02-14
No Abstract
-
Join the community and become an EASL member today! J. Hepatol. (IF 26.8) Pub Date : 2025-02-14
No Abstract
-
The THRIVE project aims to understand tumor-host interactions in adult and childhood liver cancer to develop response biomarkers and new therapies J. Hepatol. (IF 26.8) Pub Date : 2025-02-14
No Abstract
-
-
From the Editor’s Desk... J. Hepatol. (IF 26.8) Pub Date : 2025-02-14 Philip Newsome, Frank Tacke, Heiner Wedemeyer, Lorenza Rimassa, Annalisa Berzigotti, Tom H. Karlsen, Vlad Ratziu
Section snippets Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASHMRI-based biomarkers could be useful to predict histological improvement in MASH clinical trials. Alkhouri and coworkers retrieved individual patient data from 150 participants in four MASH clinical trials (ranging from 12 to 52 weeks of treatment and 18 to 104 participants) that tested
-
-
Expression of concern to “Nitric oxide mimics transcriptional and post-translational regulation during α-Tocopherol cytoprotection against glycochenodeoxycholate-induced cell death in hepatocytes” [J Hepatol. 2011 Jul;55(1):133-44] J. Hepatol. (IF 26.8) Pub Date : 2024-09-19
The editors have been alerted about potential figure inconsistencies in Figures 2B and C, 4B, and 5F.
-
Reply: AASLD Resmetirom Guidance Hepatology (IF 12.9) Pub Date : 2025-02-14 Vincent L. Chen, Timothy R. Morgan, Yaron Rotman, Heather M. Patton, Kenneth Cusi, Fasiha Kanwal, W Ray Kim
-
Letter to the Editor: Dynamics in liver stiffness to assess response in MASLD patients treated with resmetirom – one piece of the puzzle? Hepatology (IF 12.9) Pub Date : 2025-02-14 Georg Semmler, Maja Thiele, Thomas Reiberger, Mattias Mandorfer
-
Alcohol and cancer risk: bridging the awareness gap Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-02-12
No Abstract
-
Hepatitis B treatment in Africa: learning points from a scale-up programme in Ethiopia Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-02-12 Hailemichael Desalegn, Lasse Rossvoll, Fufa Hunduma, Nega Berhe, Asgeir Johannessen
No Abstract
-
Thank you to The Lancet Gastroenterology & Hepatology's statistical and peer reviewers in 2024 Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-02-12
No Abstract
-
Vedolizumab for prevention of recurrence of Crohn's disease Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-02-12 Nassim Hammoudi, Matthieu Allez
No Abstract
-
Vedolizumab for prevention of recurrence of Crohn's disease Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-02-12 Andrew Nguyen, Christopher F D Li Wai Suen, Ashish Srinivasan, Jonathan Segal, Abhinav Vasudevan
No Abstract
-
Vedolizumab for prevention of recurrence of Crohn's disease – Authors' reply Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-02-12 Geert D'Haens
No Abstract
-
Correction to Lancet Gastroenterol Hepatol 2023; 8: 976–89 Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-02-12
Vermeire S, Danese S, Zhou W, et al. Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study. Lancet Gastroenterol Hepatol 2023; 8: 976–89—In this Article, the declaration of
-
Research in Brief Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-02-12 Holly Baker
Section snippets TACE and immunotherapies for hepatocellular carcinomaTwo phase 3 trials—EMERALD-1 and LEAP-012—highlight promising advances in the treatment of unresectable hepatocellular carcinoma with transarterial chemoembolisation (TACE) combined with immunotherapeutic agents.In EMERALD-1, Bruno Sangro and colleagues randomly assigned patients with unresectable hepatocellular carcinoma amenable
-
The hitchhiker's guide to the gut Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-02-12 Cahal McQuillan
No Abstract
-
Inflammatory bowel disease in south Asia: a scoping review Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-02-12 Shabari Shenoy, Anuraag Jena, Carrie Levinson, Vishal Sharma, Parakkal Deepak, Tina Aswani-Omprakash, Shaji Sebastian, Jean-Frederic Colombel, Manasi Agrawal
Inflammatory bowel disease (IBD) is rising at an alarming rate in south Asia and there is a paucity of data on IBD in this region. For this scoping review, we conducted a systematic search to identify all observational and interventional studies on IBD in south Asia. Of 14 924 potentially eligible studies, 524 were included in this scoping review and summarised under the domains of epidemiology, natural
-
Reply to: Correspondence on ‘Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer’ J. Hepatol. (IF 26.8) Pub Date : 2025-02-12 Sohyun Hwang, Seonjeong Woo, Chan Kim, Hong Jae Chon
Section snippets Authors’ contributionsSohyun Hwang and Seonjeong Woo: Study design & Manuscript writing.Chan Kim and Hong Jae Chon: Study design & Manuscript revision. Uncited reference6.. Financial supportThis research was funded by the National Research Foundation of Korea (NRF) grants, supported by the Korean government (MSIT): grant numbers NRF-2023R1A2C2004339 to Hong Jae Chon, NRF-2023R1A2C2006375
-
Response to Zhang et al.: Evaluating Clinical Utility of CT DNA Monitoring for Recurrence Prediction in Resected Extrahepatic Cholangiocarcinoma J. Hepatol. (IF 26.8) Pub Date : 2025-02-12 Changhoon Yoo
Section snippets Authors' contributionsChanghoon Yoo: manuscript writing and final approval Financial supportNo financial support Declaration of Competing InterestCY received honoraria from Servier, Bayer, AstraZeneca, Merck Sharp & Dohme, Eisai, Roche, Celgene, Bristol Myers Squibb, Ipsen, Novartis, Boehringer Ingelheim, Boryung, Mundipharma, Autem Therapeutics, Qurient, HLB, and Elevar Therapeutics;
-
Unveiling the Molecular Legacy of Transient Insulin Resistance: Implications for Hepatic Metabolic Adaptability J. Hepatol. (IF 26.8) Pub Date : 2025-02-11 Alexandre Berthier, Céline Gheeraert, Manjula Vinod, Manuel Johanns, Loïc Guille, Joel T. Haas, Julie Dubois-Chevalier, Jérôme Eeckhoute, Bart Staels, Philippe Lefebvre
-
Neuroimmune interactions influence pancreatic glucagon secretion in fasting mice Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-02-12 Jordan Hindson
In a new study published in Science, researchers identify a mechanism in mice by which the nervous and immune systems interact to regulate blood glucose levels by controlling pancreatic glucagon secretion. First, they observed that mice with no adaptive lymphocytes and innate lymphoid cells (ILCs) (Rag2−/−Il2rg−/−) had reduced blood glucose and glucagon levels during fasting. But this effect was not
-
Global burden of HBV-related liver disease: Primary liver cancer due to chronic HBV infection increased in over one-third of countries globally from 2000 to 2021 Hepatology (IF 12.9) Pub Date : 2025-02-12 Pojsakorn Danpanichkul, Kwanjit Duangsonk, Vincent L. Chen, Preenapun Saokhieo, Disatorn Dejvajara, Banthoon Sukphutanan, Majd B. Aboona, Chawin Lopimpisuth, Yanfang Pang, Andrew F. Ibrahim, Michael B. Fallon, Daniel Q. Huang, Donghee Kim, Amit G. Singal, Ju Dong Yang, Bashar A. Aqel, Norah A. Terrault, Karn Wijarnpreecha
Backgrounds &Aims: Hepatitis B virus (HBV)-related liver disease ranks as the seventh leading cause of mortality. Despite advances in prevention and treatment, global disparities in the burden of primary liver cancer (PLC) persist. We evaluate global trends in the prevalence, incidence, and death of HBV-related liver disease. Approach and Results: Data from the Global Burden of Disease Study 2021 evaluated
-
Erratum: Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance Hepatology (IF 12.9) Pub Date : 2025-02-12 Vincent L. Chen, Timothy R. Morgan, Yaron Rotman, Heather M. Patton, Kenneth Cusi, Fasiha Kanwal, W. Ray Kim
-
Breaking the silence: MASLD and the scarcity of data on the Roma population Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-02-10 Paula Iruzubieta, Javier Crespo
No Abstract
-
Protein phosphatase 6 regulates metabolic dysfunction-associated steatohepatitis via the mTORC1 pathway J. Hepatol. (IF 26.8) Pub Date : 2025-02-11 Zhengshuai Liu, Shuang Wei, Yang Jiang, Weitong Su, Fengguang Ma, Genxiang Cai, Yuxiao Liu, Xiaoyang Sun, Ling Lu, Wenguang Fu, Yong Xu, Ruijing Huang, Jian Li, Xu Lin, Aoyuan Cui, Mengwei Zang, Aimin Xu, Yu Li
-
A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH J. Hepatol. (IF 26.8) Pub Date : 2025-02-10 Stephen A. Harrison, Naim Alkhouri, Grisell Ortiz-Lasanta, Madhavi Rudraraju, Dean Tai, Katy Wack, Amrik Shah, Robin Besuyen, Hilde H. Steineger, David.A. Fraser, Arun J. Sanyal
-
Metabolic dysfunction-associated steatotic liver disease a multisystem disease: assessing the cost effectiveness of pharmacotherapies J. Hepatol. (IF 26.8) Pub Date : 2025-02-10 Christopher D. Byrne, Gregory J. Dore
No Abstract
-
Targeting protein hyperSUMOylation halts cholangiocarcinoma progression by impairing cancer cell viability and tumor-stroma crosstalk Hepatology (IF 12.9) Pub Date : 2025-02-11 Paula Olaizola, Irene Olaizola, Ainhoa Lapitz, Beatriz Val, Laura Izquierdo-Sanchez, Maite G. Fernandez-Barrena, Colm J. O’Rourke, Pui Y. Lee-Law, Andreea Gradinaru, Raul Jimenez-Agüero, Adelaida La Casta, Ioana Riaño, Rocio I.R. Macias, Jose J.G. Marin, Maria L. Martinez-Chantar, Matias A. Avila, Patricia Aspichueta, Jesper B. Andersen, Luke Boulter, Luis Bujanda, Pedro M. Rodrigues, Maria J. Perugorria
Background and Rationale: Cholangiocarcinoma (CCA) includes a diverse group of biliary malignancies with poor prognosis. Alterations in post-translational modifications contribute to disrupted protein dynamics, cellular disturbances, and disease. This study investigates the role of protein SUMOylation in cholangiocarcinogenesis and its potential as a therapeutic target. Approach and Results: Analysis
-
Author Correction: Understanding the therapeutic toolkit for inflammatory bowel disease Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-02-10 Sophie Vieujean, Vipul Jairath, Laurent Peyrin-Biroulet, Marla Dubinsky, Marietta Iacucci, Fernando Magro, Silvio Danese
Correction to: Nature Reviews Gastroenterology & Hepatology https://doi.org/10.1038/s41575-024-01035-7, published online 31 January 2025.
-
Aptamer-directed, nanovesicle-mediated targeting of undruggable molecules in preclinical cholangiocarcinoma models Hepatology (IF 12.9) Pub Date : 2025-02-10 Mincheng Yu, Jack W. Sample, Irene K. Yan, Shohei Takaichi, Jennifer L. Tomlinson, Emilien J. Loeuillard, Ryan D. Watkins, Nathan W. Werneburg, Amro M. Abdelrahman, Danielle Carlson, Hendrien Kuipers, Meina Cai, Enis H. Ozmert, Brooke Kimball, Jinchun Yang, Sumera I. Ilyas, Gregory J. Gores, Tushar Patel, Rory L. Smoot
Background and Aims: Cholangiocarcinoma (CCA) is an aggressive malignancy arising from the biliary epithelium with limited therapeutic options and poor long-term survival rates. To address the limitations in CCA treatment, we investigated cell-targeted nanovesicles as a delivery platform for transcriptome-targeting therapeutics. Approach & Results: Milk-derived nanovesicles (MNVs) were loaded with
-
Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment Hepatology (IF 12.9) Pub Date : 2025-02-10 Qingran Liu, Jinpeng Li, Hua Chen, Jinlong Song
-
Reply to: “Optimizing Antiviral Prophylaxis Strategies: Insights and Reflections on a Real-World Study” and “Optimal Timing To Initiate Antiviral Prophylaxis of MTCT: More Required to Be Done” J. Hepatol. (IF 26.8) Pub Date : 2025-02-08 Mingwang Shen, Shihao He, Naijuan Yao, Li Xie, Lei Zhang, Tianyan Chen
Section snippets Authors' contributionsMS, LZ, TC, and SH conceived and designed the study. MS and SH analyzed the data, carried out the analysis, and performed numerical simulations. MS and SH wrote the first draft of the manuscript. MS, LZ, and TC critically revised the manuscript. All the authors contributed to writing the paper and agreed with the manuscript results and conclusions. Data availability
-
Reply to: “Evaluating Fracture Risk with TDF in Elderly Hepatitis B Patients: A Korean Perspective” J. Hepatol. (IF 26.8) Pub Date : 2025-02-08 Jimmy Che-To Lai, Jie Cai, Terry Cheuk-Fung Yip
Section snippets AcknowledgementsNone. Authors' contributionsAll authors were responsible for writing the article. All authors read and approved the final version of the manuscript. Financial supportNone declared. Declaration of Competing InterestJimmy Lai has served as a speaker for Gilead Sciences and Abbott, and an advisory committee member for Gilead Sciences and Boehringer Ingelheim. Cai J declares
-
Treatment coverage of the 2024 updated WHO guidelines for patients with chronic hepatitis B J. Hepatol. (IF 26.8) Pub Date : 2025-02-08 Jian Wang, Shaoqiu Zhang, Chuanwu Zhu, Chao Wu, Rui Huang
Section snippets Authors' contributionsDr. Huang had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.Concept and design: Huang, Wang, Wu.Acquisition, analysis, or interpretation of data: All authors.Drafting of the manuscript: Wang, Huang.Critical review of the manuscript for important intellectual content: Huang
-
Pathogens don't respect politicians: US federal disruption poses a new threat to global public health Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-02-06 Su Wang, Mark Harrington, Camilla S Graham, Louise O Downs, Nancy Kagwanja, Anthony O Etyang, Collins Iwuji, Thumbi Ndung'u, Benjamin C Cowie, Kenneth Kabagambe, Philippa C Matthews
No Abstract
-
Revealing bias in feature importance through PLS-DA: A critical examination of machine learning applications in chronic liver disease J. Hepatol. (IF 26.8) Pub Date : 2025-02-07 Yoshiyasu Takefuji
Section snippets Financial supportThe author did not receive any financial support to produce this manuscript. Conflict of interestThe author declares no conflict of interest.Please refer to the accompanying ICMJE disclosure form for further details.
-
Bridging the gap between science and survival Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-02-07 Ahsen Ustaoglu
A scientist’s personal journey through breast cancer underscores the urgency for greater empathy in research and healthcare, a patient-centred approach to data dissemination, and more comprehensive, streamlined support for early-career researchers navigating health crises.
-
Overcoming the challenges of overtreating and undertreating inflammatory bowel disease Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-02-06 Maria José Temido, Sailish Honap, Vipul Jairath, Severine Vermeire, Silvio Danese, Francisco Portela, Laurent Peyrin-Biroulet
Several therapeutic advances have been achieved over the past two decades for inflammatory bowel disease (IBD). The expanding therapeutic armamentarium and the increasingly ambitious treatment targets have led to an increased use of advanced therapies and better outcomes. Nevertheless, many patients remain suboptimally treated and are at risk of disease progression, hospital admission, and surgery
-
Identifying the sweet spot in portal pressure reduction with TIPS Hepatology (IF 12.9) Pub Date : 2025-02-06 Louise China, David Patch
-
Hyodeoxycholic acid ameliorates cholestatic liver fibrosis by facilitating m6A-regulated expression of a novel anti-fibrotic target ETV4 J. Hepatol. (IF 26.8) Pub Date : 2025-02-04 Xiaoyong Xue, Runping Liu, Yajie Cai, Liping Gong, Guifang Fan, Jianzhi Wu, Xin Li, Xiaojiaoyang Li
-
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2025-02-05 Timothy M. Block, Ju-Tao Guo, Fabien Zoulim, Charles M. Rice, Chloe L. Thio, William M. Schneider, Harvey J. Alter, Ira M. Jacobson, Robert G. Gish, Peter D. Block, Mark Sulkowski, Jordan J. Feld, Chari A. Cohen
-
Coil or Plug-Assisted Retrograde transvenous obliteration (CARTO/PARTO) for treating portal hypertensive variceal bleeding: A multi-center, real-world 10-year retrospective study Hepatology (IF 12.9) Pub Date : 2025-02-05 Edward Wolfgang Lee, Sammy Saab, Navid Eghbalieh, Peng-xu Ding, Ung Bae Jeon, Joon Young Ohm, Ronnie C. Chen, Man-Deuk Kim, Kichang Han, Dong Jae Shim, Jong Soo Shin, Anirudh Mirakhur, Chien-An Liu, Jonathan Park, Frank Hao, Man Wong, Antonio Moreno, Jasleen Singh, Fady Kaldas, Douglas G. Farmer, Juan Gonzalez-Abraldes
Background & Aims: CARTO and PARTO are well-accepted treatment for gastric variceal (GV) bleeding. However, long-term (>2 years) clinical outcomes have yet to be studied. In this study, we investigated long-term clinical outcomes, including overall survival (OS) in 10 years Methods: We performed a multi-national, multi-center, retrospective study of CARTO/PARTO in GV treatments between 05/2012 and
-
Reply: Interpreting the 100% disease control rate of Sin-Bev-RT in HCC with PVTT Hepatology (IF 12.9) Pub Date : 2025-02-05 Zelong Liu, Meiyan Zhu, Zhenwei Peng
-
Applying the estimand framework to inflammatory bowel disease clinical trials Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2025-02-03 Nurulamin M Noor, Maria Manuela Estevinho, Virginia Solitano, Yuhong Yuan, Brennan C Kahan, Vipul Jairath
No Abstract